Mespere Lifesciences Inc.
11
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Non-Invasive Jugular Venous Blood Volume Assessment (BVI)
Role: collaborator
Pilot Study of a Non-Invasive Central Venous Pressure Monitoring System in Children
Role: collaborator
ED Decision Making Among Hypotensive Patients
Role: lead
Comparison of Central Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter
Role: lead
Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter
Role: lead
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
Role: lead
Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions
Role: lead
Accuracy of Oximeters With Hypoxia and Methemoglobin or Carboxyhemoglobin
Role: lead
Correlation of Measurements From Mespere Venus 1000 System & Echocardiography to Estimate Right Atrial Pressure
Role: lead
Comparison of a Non-Invasive Central Venous Pressure Device and Physical Examination in Patients With Chronic Kidney Disease
Role: lead
Correlation of Physical Exam Versus Non-invasive Assessment Versus Invasive Assessment of Central Venous Pressure
Role: lead
All 11 trials loaded